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Legislative Mandate 
 
The following report is hereby issued pursuant to Section 25A of Chapter 112 of the 
Massachusetts General Laws as follows:  
 
Section 25A. The board shall submit an annual report to the department of public health, the joint 
committee on public health and the joint committee on health care financing on or before 
December 31. The report shall detail the investigatory and disciplinary actions conducted by the 
board and shall detail: (1) each complaint received by the board or initiated by the board; (2) the 
date of the complaint; (3) the violation alleged; (4) the name of any state or federal agency that 
collaborated with the investigation; (5) the summary of the final decision of the board to: (i) 
dismiss the complaint, (ii) impose an informal sanction or penalty, (iii) impose a formal sanction 
or penalty or (iv) amend a previously issued sanction or penalty; and (6) whether the board 
reported the result of its investigation to another state board, federal agency or external entity. 
 
All relevant data collected and analyzed under subsections (b) to (e), inclusive, of section 39D 
shall be summarized and included in the report. The report shall be made available, including by 
electronic means, to the public and all hospitals, pharmacies and health care providers doing 
business in the commonwealth. Said report shall be posted on the department of public health's 
website. 
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Executive Summary 
 
The enactment of Chapter 159 of the Acts of 2014, An Act Relative to Pharmacy Practice in the 
Commonwealth, brought with it many new requirements and opportunities for the Board of 
Registration in Pharmacy (Board).  This report, entitled “Investigatory & Disciplinary Actions 
Conducted by the Board of Registration in Pharmacy” is intended to track all complaints that 
moved through the Board from December 1, 2015 to December 1, 2016.  This is the fourth 
annual report. 
 
Each year the Board must track and report (1) each complaint received by the board or initiated 
by the board; (2) the date of the complaint; (3) the violation alleged; (4) the name of any state or 
federal agency that collaborated with the investigation; (5) the summary of the final decision of 
the board to: (i) dismiss the complaint, (ii) impose an informal sanction or penalty, (iii) impose a 
formal sanction or penalty or (iv) amend a previously issued sanction or penalty; and (6) whether 
the board reported the result of its investigation to another state board, federal agency or external 
entity.  
 
The Board and staff have continued to work diligently to conduct investigations and process 
cases expeditiously.  In 2016, much progress has been made including the following: 
 
 The continued expedited processing of complaints and staff assignments; 
 The heightened monitoring of drug losses and other drug violations; 
 A decrease in non-disciplinary dispositions with the continued implementation of Just 
Culture through the use of voluntary anticipatory continuing education credits for 
specified complaint types; 
 The continued collaboration with local, state and federal agencies; 
 A continued robust field presence uncovering regulatory violations and inspectional 
deficiencies; and 
 A focus on information gathering at the investigation level prior to initiating formal 
complaints. 
 
Since the first annual report in 2013, the processes put in place have allowed the Board and 
Board staff to move cases through the system at an accelerated pace.  A thorough investigation 
and well written report allows the Board to resolve these cases quickly.  The goal is to continue 
to fine-tune the Board’s processes and procedures and ensure that quality improvement is 
monitored, continuing in 2017 and beyond. 
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Introduction 
 
Following the 2012 multi-state meningitis outbreak that was attributed to products from a 
Massachusetts-based pharmacy, legislation containing sweeping pharmacy practice reform was 
signed into law.  Immediately after the outbreak, the Board began implementing regulatory and 
administrative reforms to improve oversight of the compounding pharmacy industry.  
Specifically, the Board staff instituted new or updated existing administrative procedures, 
including:  priorities for complaint investigations; timelines and guidelines for standard 
investigation activities; guidelines for handling evidence and chain of custody logs; and 
processes for complaint intake and triage.  Additionally, Board staff developed new policies and 
procedures, including:  managing communication about abnormal test results; managing above 
action limit1 environmental monitoring results; pharmacy retail drug store closures; and handling 
incoming reports of theft or loss of controlled substances.  These efforts helped the Board 
achieve its goal of enhanced oversight of the compounding pharmacy industry, as well as 
traditional retail pharmacies. 
 
This annual report tracks all pharmacy complaints that were either pending, received, initiated, or 
opened during the period December 1, 2015-December 1, 2016. 
 
Case Flow Overview 
 
To provide context to the enclosed report an overview of the Board’s case flow is provided.2  
The Board receives initial complaints alleging regulatory violations or other misconduct against 
a licensee.  At a weekly pharmacy triage meeting, Board staff determines whether the 
allegations, if true, assert a violation of laws or regulations governing the practice of pharmacy 
by the particular licensee, and take one of three actions. 
 
If they determine that the facts alleged, if true, would not constitute a violation, Board staff will 
close the matter.  If they determine that the facts alleged do constitute a violation and that there is 
clear evidence supporting the allegations, Board staff open a formal disciplinary Complaint 
(Complaint).  If further information is needed to make the determination, Board staff open an 
Investigation. 
 
In the case of both Complaints and Investigations, Board staff conducts further investigation as 
necessary.  If the evidence gathered in an Investigation clearly supports a violation, the 
Investigation may be immediately converted into a Complaint.  If the Investigation does not 
yield clear evidence supporting a violation against a particular licensee, the Investigation is 
presented to the Board to determine if a complaint should be opened or the matter should be 
closed. 
 
                                                 
1 The level which requires a pharmacy engaged in sterile compounding to take remedial measures. 
2 See Appendix A:  Case Flow Diagram. 
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As part of the investigation, the investigator contacts the licensee for a response to the 
allegations.  The investigators also obtain evidence, as available, from complainants3 and other 
witnesses.  When the investigation is complete, the investigator writes a report.  The report is 
then reviewed by the Director of Investigations to ensure accuracy and completeness. 
 
Next, the Director of Pharmacy Investigations determines whether the Complaint will be 
presented to the Board or go to the Board Delegated Complaint Review (BDCR) committee.4  
The BDCR has authority to dispose of Investigations or Complaints that fall under Board-
specified criteria. 
 
If the Complaint is outside of the BDCR criteria, the Complaint will be slotted for review on a 
Board meeting agenda and subsequently presented to the Board.  Following the Board meeting 
review, the Board members may take the following actions:  (1) dismiss the matter; (2) request 
further investigation; (3) authorize commencement of disciplinary proceedings; and/or (4) 
authorize terms for resolution of the Complaint by consent agreement. 
 
In reviewing the data presented in Appendices B, C, and D, you will notice that the length of 
investigation and length of time until resolution of these cases may vary considerably.  Various 
factors may contribute to the length of a case staying open including: complexity, availability of 
evidence or witnesses, concurrent criminal matters where Board cases may be delayed or placed 
on hold, lengthy administrative hearings, appeal of final decisions, etc.  Appendices E through Q 
summarize relevant information captured in the overall data. 
 
Data Structure 
 
The data is separated into three (3) sections: 
 
1. Formal Complaints; 
2. Investigations;  and 
3. Preventable Medication Errors. 
 
For all cases listed, the report indicates the number assigned to each case, the name and license 
number of the licensees involved, the violation alleged,5 and if the case is beyond the 
investigation stage, the name of any local, state or federal agency that collaborated in the 
investigation.  For each of the cases handled by the Board during the above-listed time frame, a 
chronological account of the Board actions taken is indicated as follows: 
 
For Complaints, the date the investigation was opened, the date it was sent to the Board for 
Board action, the date it went to Board Counsel, the date it was sent to Prosecution, and the date 
                                                 
3 Complainant: a person who makes a formal charge in an administrative proceeding or court saying that someone 
has done something wrong. 
4 The BDCR consists of at least one Board member and at least the following Board staff: (1) the Executive Director 
or his/her designee; (2) Director of Compliance or his/her designee; and (3) Board Counsel. 
5 Violations marked “Serious Reportable Event” pertains to a pharmacy’s requirement to report to the Board any 
improper dispensing of a prescription drug that results in serious injury or death.  Violations marked “Other” are 
instances that do not fall under typical categories the licensure database.  Each year, the files in this category are 
reviewed to determine if new categories need to be established. 
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the case was closed.  If the docket is closed, the result is provided.  If the result was discipline on 
a license, the report indicates if the discipline was externally reported.  If a “not applicable 
(N/A)” is noted, it indicates that the Investigation or Complaint did not proceed to that stage or 
does not yet have a final decision. 
 
For Investigations, the date the Investigation was opened, the date it was closed, and the date 
any Complaint docket was opened as a result of the Investigation are included.  An Investigation 
cannot result in discipline because it would first have to be converted to a Complaint, and for that 
reason, no results of Investigations have been reported externally. 
 
The report of Preventable Medication Errors details all available information for Complaints 
and Investigations where the alleged violation was related to a medication error.  For each 
medication error, the report indicates a synopsis of the medication error.  Redundant errors are 
typically companion cases related to the same medication error, for all responsible licensees 
(pharmacy, pharmacist, pharmacy intern, pharmacy technician, etc.) 
 
This Report is comprised primarily of data that has been collected and analyzed from December 
1, 2015 through December 1, 2016.  The data presented in the Excel spreadsheets in Appendices 
B, C, and D contain all of the information that has been collected.  Appendices E through Q 
contain an analysis of the information as well as charts to show a quick examination of the data, 
easily compare data sets and emphasize trends. 
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Conclusion 
 
The systematic changes and improvements that have been put in place over the last four years 
reflect a Board that has policies and procedures that are clear, effective, and efficient.  In 
addition, these changes also support a group of pharmacy investigators that continue to have a 
commanding field presence which they utilize to educate the pharmacy community on 
compliance standards, ultimately leading to improved compliance with pharmacy laws and 
regulations. 
 
This report details all formal complaints and investigations that were pending, received, initiated, 
or opened by the Board during the period of December 1, 2015 through December 1, 2016.  
Significant progress has been made including the following: 
 
 In 2016, Board staff continued the efficient processing system established in 2014.  
Overall, the data depicts that the high rate of case closures established in 2014 was 
maintained in 2016, despite the rise of opening volume. 
 The Board continued to process cases expeditiously in 2016, resulting in an 86.7% 
increase in case closures since 2013. 
 The total number of investigations that were opened in 2016 increased from previous 
years.  The increase is attributed to a focus during the intake process to refrain from 
opening formal complaints against licensees unless there is clear evidence of a violation. 
 Board staff continued to monitor controlled substance loss reports (classified as “Drug 
Violations”) and encourage self-reports of continuing education deficiencies, resulting in 
an increase in investigations related to these events. 
 A continued and significant field presence in 2016 uncovered regulatory violations and 
inspectional deficiencies resulting in formal complaints.  Investigators continue to pay 
close attention to the reports of drug losses and diversions, resulting in formal complaints 
for this type (classified as “Drug Violations”). 
 The most common complaint type, “Failure to Fill RX Properly,” showed a significant 
decrease as complaint volume stabilizes.  The high number of “Failure to Fill RX 
Properly” complaints in 2014 was an anomaly, as many of them were backlogged 
complaints from previous years with new companion complaints processed in 2014. 
 The Board and staff continue to forge strong relationships with our local, state and 
federal partners and will collaborate on cases where doing so is in the best interest of 
public health and safety. 
 
As the Board and staff move forward they intend to continue monitoring and making quality 
improvements in the investigation and processing of formal complaints and investigations.  This 
allows the Board to make informed and expeditious decisions on the numerous complaints that 
are received each year; all with the primary goal of protecting the health, safety and welfare of 
the public. 
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Appendix A:  Case Flow Diagram 
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Appendix B:  Formal Complaint Data 
 
Please see separate Excel spreadsheet data. 
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Appendix C:  Investigation Data 
 
Please see separate Excel spreadsheet data. 
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Appendix D:  Medication Error Data 
 
Please see separate Excel spreadsheet data. 
13 
 
Appendix E:  Investigation Statuses 
 
 
 
 
 
Status 2013 2014 2015 2016 
Open 63 31 74 69 
Pending Board 52 50 26 42 
Pending Further Investigation 0 0 1 20 
Pending Legal 0 2 2 2 
Closed 76 136 144 211 
Total 191 219 247 344 
 
 
What this means:  The total number of active investigations in 2016 increased from previous 
years.  The increase is attributed to a focus on evaluating the evidence available at the time of 
intake.  If there is not clear evidence of a violation, Board staff will open an investigation to 
gather evidence in an attempt to substantiate the allegations.  This practice has led to an increase 
in investigations.  The total number of closed investigations in 2016 shows a continued increase 
in the efforts of the Board and staff to process cases expeditiously. 
0
25
50
75
100
125
150
175
200
225
Open Pending Board Pending Further
Investigation
Pending Legal Closed
N
u
m
b
e
r 
o
f 
In
v
e
s
ti
g
a
ti
o
n
s
Investigation Status
Investigation Statuses
2013
2014
2015
2016
14 
 
Appendix F:  Investigation Dispositions 
 
 
 
 
 
Disposition 2013 2014 2015 2016 
Resulting in Complaint 24 21 35 41 
Closed 43 109 109 170 
 
 
What this means:  As described in Appendix E, the Board and staff processed more cases in 
2016, resulting in a maintained increase in case closures.  Many of the investigations were closed 
and formal complaints were not opened because they did not rise to the level of a Board 
regulation or statutory violation or for the lack of evidence to substantiate that a violation 
occurred. 
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Appendix G:  Most Common Investigation Types 
 
 
Investigation Type 2013 2014 2015 2016 
Drug Violation 32 62 61 95 
Regulatory Violation 18 27 31 71 
General Practice Standards 16 17 33 63 
Abnormal Report n/a n/a 40 37 
Other 27 52 19 19 
Inspectional Deficiencies 21 7 17 18 
Failure to Fill Rx Properly 28 28 21 17 
 
What this means:  During 2016, Board staff continued to monitor controlled substance loss 
reports (classified as “Drug Violations”) resulting in a significant increase in investigations 
related to these losses.  In 2016, the Board instituted Policy 16-02 in an effort to expedite such 
investigations, informing all licensees of the information that is required for the most frequent 
controlled substance loss investigations.  The Board continued to see an increase in the number 
of “Regulatory Violations” due to the encouragement of self-reporting continuing education 
deficiencies following the 2014 implementation of new continuing education requirements as 
required by law.  Despite issuing an Alert shortly after the statute was signed into law, many of 
these self-reports were due to licensee confusion over the new requirements.  To address this, the 
board issued in-depth Guidance, and licensees who self-reported continuing education 
deficiencies were given the opportunity to correct the deficiency prior to the investigation being 
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presented to the Board, rather than a formal complaint opened against their license with non-
disciplinary stayed probation effective until the deficiency was corrected. The Board will 
continue to take measures to increase awareness among licensees of the continuing education 
requirements. 
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Appendix H:  Other Investigation Types 
 
Investigation Type 2013 2014 2015 2016 
Criminal Activity 0 1 6 8 
Confidentiality Violation 1 1 2 5 
Delay in Therapy 0 0 11 4 
Unprofessional Conduct 8 7 3 2 
Practicing Beyond Scope 0 0 1 2 
Unethical Conduct 1 0 1 2 
Inadequate/Fraudulent Documentation 0 0 1 1 
Good Moral Character Evaluation 39 10 0 0 
Practice While Impaired 0 1 0 0 
Request for Inspection 1 0 0 0 
Substance Abuse 1 0 0 0 
 
What this means:  In 2016, the Board saw a slight increase in the number of criminal activity 
investigations.  This is the result of the encouragement of self-reporting of criminal arrests, as 
required by 247 CMR 10.00.  Those licensees that reported criminal arrests which were not 
related to the practice of pharmacy were investigated and presented to the Board, but formal 
complaints were not opened.  The largest decrease in investigations is still “Good Moral 
Character Evaluation,” which was removed from investigations entirely and shifted to an 
administrative process conducted by Board staff in 2014. 
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Appendix I:  Investigations by License Type 
 
 
 
 
Investigations by License Type 2013 2014 2015 2016 
Drug Store 123 177 202 261 
Pharmacist 21 20 35 68 
Pharmacy Technician 10 11 5 9 
Nuclear Pharmacy 0 0 1 3 
Wholesale Distributor 1 2 3 2 
Pharmacy Intern 2 1 1 1 
Unlicensed 33 2 0 0 
 
 
What this means:  In keeping with historical figures, Drug Stores had the highest number of 
investigations of all license types.  Investigations typically start against Drug Stores, as the Drug 
Store maintains and holds the records surrounding the alleged incidents.  Once information is 
obtained from Drug Stores and reviewed, related companion cases are opened against any 
individual licensees involved in the alleged incidents whose conduct constitutes a violation of 
applicable regulation or statute. 
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Appendix J:  Formal Complaint Statuses 
 
 
 
Status 2013 2014 2015 2016 
Pending Investigation 55 42 45 84 
Pending Board Action 102 58 17 70 
Pending Board Counsel 84 126 64 31 
Pending Prosecution 48 42 43 30 
Pending Hearing Officer 0 4 1 9 
Pending Administrative Hold 0 0 0 1 
Closed 151 284 267 197 
Total 440 556 437 422 
 
 
What this means:  In 2016, Board staff maintained the expedited formal complaint processing 
system established in 2014.  Most importantly, the data depicts that the Board continued to 
process all complaints that were waiting to be heard by the Board.  At the end of 2016, 
complaints that are updated to Pending Board are routinely heard at the next scheduled Board 
meeting.  The data additionally shows a rise in new complaint volume during 2016.  To 
accommodate the rising volume, field-based investigators that handle inspections are training to 
investigate complaints.  The cross-training of all investigators will allow the Director of 
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Pharmacy Investigations to allocate field-based and office-based staff based on operational 
needs. 
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Appendix K:  Formal Complaint Dispositions 
 
 
 
Disposition 2013 2014 2015 2016 
Resulting in Discipline 51 74 74 70 
Resulting in Non-Discipline 26 78 83 13 
Dismissed 69 120 110 114 
 
What this means:  In keeping with the continued implementation of a Just Culture6, beginning in 
2016, licensees were given the opportunity to self-remediate complaints related to medication 
errors by completing continuing education credits in anticipation of the Board hearing their 
respective complaint.  This new opportunity has resulted in many of the complaints being 
dismissed for discipline not warranted, and a significant decrease in complaints resulting in non-
discipline. 
                                                 
6 A Just Culture recognizes that individual practitioners should not be held accountable for system failings over 
which they have no control.  A Just Culture also recognizes many individual or “active” errors represent predictable 
interactions between human operators and the systems in which they work.  However, in contrast to a culture that 
touts “no blame” as its governing principle, a Just Culture does not tolerate conscious disregard of clear risks to 
patients or gross misconduct (e.g., falsifying a record, performing professional duties while intoxicated).  Excerpted 
from: Marx D. Patient Safety and the “Just Culture”: A Primer for Health Care Executives.  New York, NY: 
Columbia University; 2001.  Available at: 
http://www.safer.healthcare.ucla.edu/safer/archive/ahrq/FinalPrimerDoc.pdf 
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Appendix L:  Most Common Complaint Types 
 
 
 
Complaint Type 2013 2014 2015 2016 
Failure to Fill Rx Properly 162 229 142 128 
Drug Violation 54 73 70 100 
Inspectional Deficiencies 65 60 79 79 
Regulatory Violation 23 47 48 41 
Serious Reportable Event (SRE) 18 62 53 30 
General Practice Standards 52 27 18 16 
 
What this means:  The most common complaint type, “Failure to Fill RX Properly,” showed 
a significant decrease again this year.  However, on closer examination, the high number of 
“Failure to Fill RX Properly” complaints in 2014 was an anomaly, as many of them were 
backlogged complaints from previous years with new companion complaints processed in 
2014.  A continued and significant field presence in 2016 uncovered regulatory violations 
and inspectional deficiencies resulting in formal complaints.  Investigators continue to pay 
close attention to the reports of drug losses and diversions, resulting in formal complaints for 
this type (classified as “Drug Violations”). 
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Appendix M:  Other Complaint Types 
 
 
 
Complaint Type 2013 2014 2015 2016 
Criminal Activity 2 1 1 9 
Discipline in Another Jurisdiction 25 25 8 4 
Unethical Conduct 1 0 2 4 
Unlicensed Practice 5 2 4 3 
Other 9 5 4 3 
Confidentiality Violation 5 4 2 2 
DOR Notice 1 1 2 2 
Delay in Therapy 0 0 0 1 
Breach of Contract 3 3 2 0 
Abnormal Report 0 0 1 0 
Criminal Conviction 0 0 1 0 
General Misconduct 1 0 0 0 
Practice While Impaired 1 1 0 0 
Substance Abuse 1 0 0 0 
Summary Action 8 4 0 0 
Unprofessional Conduct 2 0 0 0 
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What this means:  The most significant change in 2016 was the rise in “Criminal Activity” 
complaints.  The rise is attributed to Board outreach efforts that have focused on reminding 
licensees of mandatory reporting requirements of any pending criminal charges or convictions.  
The Board has had cases where circumstances caused immediate threat to health and safety; 
however, Board staff quickly identified these cases and worked with pharmacy staff who 
voluntarily ceased unsafe practices.  Without voluntary action the Board would have taken 
summary action. 
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Appendix N:  Complaints by License Type 
 
 
 
Complaints by License Type 2013 2014 2015 2016 
Drug Store 151 195 194 203 
Pharmacist 176 238 165 133 
Pharmacy Technician 104 100 71 76 
Pharmacy Intern 3 9 5 6 
Wholesale Distributor 2 2 2 2 
Nuclear Pharmacy 0 0 0 1 
Unlicensed 2 1 0 1 
 
 
What this means:  In 2016, the Board opened the most complaints against Drug Stores.  As 
described in Appendix I for investigations, complaints also typically begin with Drug Stores and 
after additional information is received, related companion cases are opened against individual 
licensees involved in the alleged incidents.  Although the largest groups, Drug Stores and 
Pharmacists, appear to decrease in volume in 2016, the higher totals in previous years are an 
anomaly, as many of them were backlogged complaints from previous years.  These decreases 
are also attributed to the focus on gathering evidence through investigations rather than 
complaints, as described in Appendix E. 
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Appendix O:  Collaboration with Outside Agencies 
 
 
 
 
 
 
Collaboration with Outside Agencies 2013 2014 2015 2016 
Complaints 42 60 49 67 
Investigations 20 26 16 25 
 
 
What this means:  In 2016, the investigators continued to collaborate with outside agencies.  
Statistically, this number appears to increase.  The Board and Board staff continue to forge 
strong relationships with our local, state and federal partners and will collaborate on cases where 
doing so is in the best interest of public health and safety.  Board staff attributes the increases in 
files with collaborating agencies to the increase in volume of files of specific types.  Board staff 
often collaborates with outside agencies on alleged Drug Violations, Criminal Activity, 
Regulatory Violations, General Practice Standards and Inspectional Deficiencies cases, all of 
which increased or maintained their volume in 2016.   
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Appendix P:  Case Openings 
 
 
 
 
 
 
 
 
 
What this means:  In 2016, there was an increase in the number of openings, corresponding to 
both Complaints and Investigations.  Staff attributes these increases in case volume to the 
increased number of investigators on hand to inspect pharmacies, resulting in increases in 
inspectional deficiency and regulatory/code violation cases.  In addition, increased monitoring of 
reported drug losses has resulted in increased drug violation cases and increased continuing 
education requirements for all pharmacists and compounding continuing education requirements 
for compounding staff has also resulted in increased continuing education related 
regulatory/code violation cases. 
0
50
100
150
200
250
Complaints Investigations
N
u
m
b
e
r 
o
f 
C
a
s
e
s
Type of Case
Case Openings
2013
2014
2015
2016
Openings 2013 2014 2015 2016 
Complaints 208 252 164 226 
Investigations 129 100 163 211 
28 
 
Appendix Q:  Case Closings 
 
 
 
 
 
 
 
 
 
 
 
What this means:  In 2016, the Board closed a total of 424 cases, a slight increase from cases 
closed in 2014 and 2015, and a 86.7% increase over closings in 2013.  Investigators and Board 
staff continue to work diligently to conduct investigations and process cases expeditiously. 
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